Desley van Zoggel

17. Mandard A -M, Dalibard F, Mandard J -C, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer. 1994;73:2680–2686. 18. Cercek A, GoodmanKA, Hajj C, et al. Neoadjuvant chemotherapy first, followed by chemoradiation and then surgery, in the management of locally advanced rectal cancer. J Natl Compr Canc Netw. 2014;12:513–519. 19. De Campos-Lobato LF, Stocchi L, Da Luz Moreira A, et al. Pathologic complete response after neoadjuvant treatment for rectal cancer decreases distant recurrence and could eradicate local recurrence. Ann Surg Oncol. 2011;18:1590–1598. 20. Ishiba T, Ohtsukasa S, Kato S, et al. [A case of pathologically complete response of local recurrence in the mesorectum after multidisciplinary therapy.]. Gan To Kagaku Ryoho. 2013;40:1993–1995. 21. Iwata N, Ishikawa T, Takahashi H, et al. [A case of recurrent rectal cancer successfully treated for a long periodwith capecitabine plus oxaliplatin andbevacizumab therapy.]. GanToKagakuRyoho.;40. 22. Yatsuoka T, Nishimura Y, SakamotoH, et al. [Acase of recurrent rectal cancer with paraaortic lymph nodemetastasis treated by FOLFIRI therapy leading to complete response.]. Gan To Kagaku Ryoho. 2011;38:2057–2059. 23. Denost Q, Kontovounisios C, Rasheed S, et al. Individualizing surgical treatment based on tumour response following neoadjuvant therapy in T4 primary rectal cancer. Eur J Surg Oncol. 2017;43:92– 99. 24. Rouanet P, Rullier E, Lelong B, et al. Tailored Treatment Strategy for Locally Advanced Rectal Carcinoma Based on the Tumor Response to Induction Chemotherapy: Preliminary Results of the French Phase II Multicenter GRECCAR4 Trial. Dis Colon Rectum. 2017;60:653–663.